AG
OCUL icon

Advisor Group’s Ocular Therapeutix OCUL Stock Holding History

Advisor Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,800
Closed -$12K – 4583
2016
Q3 		$12K Buy
+1,800
New +$11K ﹤0.01% 3453

Other funds holding OCUL

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Advisor Group's OCUL Position: Q4 2016 in Review

Advisor Group sold out of Ocular Therapeutix (OCUL) in Q4 2016, closing a stake of 1,800 shares — an estimated $12K sold.

Advisor Group first reported a position in OCUL in Q3 2016 and held it in 1 quarter. The position peaked at $12K in Q3 2016. 76 funds tracked by Wall St. Rank hold OCUL as of Q4 2016.

  • Advisor Group reported no remaining Ocular Therapeutix position as of Q4 2016 after selling out during the quarter.
  • Advisor Group sold 1,800 Ocular Therapeutix shares in Q4 2016, an estimated $12K.
  • Advisor Group first reported a position in Ocular Therapeutix in Q3 2016 and held it in 1 quarter.
  • Advisor Group's Ocular Therapeutix position peaked at $12K in Q3 2016.
  • 76 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2016.

Based on Advisor Group's 13F filing for Q4 2016, filed 31 Jan 2017.